TP53 and neoplasm: Shikonin has been shown to suppress tumor growth by modulating multiple signaling pathways including p21, PI3K, ERK, and p53 (Jeung et al. 2016), and overcome cancer drug resistance such as gefitinib-resistance by inhibiting TrxR and activating the EGFR proteasomal degradation pathway (Li et al. 2017).